ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » Vasculitis – Non-ANCA-Associated and Related Disorders Poster I: Giant Cell Arteritis

Date: Saturday, November 12, 2022

Time: 1:00PM-3:00PM

Meeting: ACR Convergence 2022

1:00PM-3:00PM
Abstract Number: 0479
A Prospective Study Evaluating the Utility of Ultrasound in Monitoring Newly-Diagnosed GCA
1:00PM-3:00PM
Abstract Number: 0487
A Systematic Literature Review to Generate Descriptors for the Development of New Response Criteria in Giant Cell Arteritis
1:00PM-3:00PM
Abstract Number: 0467
All-Cause and Cause-Specific Mortality in Giant Cell Arteritis, a Population-based Study
1:00PM-3:00PM
Abstract Number: 0490
Analysis of Emergency Department Visits by Patients with Giant Cell Arteritis: A National Population-based Study
1:00PM-3:00PM
Abstract Number: 0485
Assessing the Effectiveness of Tocilizumab in Newly Diagnosed Giant Cell Arteritis versus Refractory/recurrent Giant Cell Arteritis in Clinical Practice
1:00PM-3:00PM
Abstract Number: 0466
Assessment of Probability Scores to Predict Giant Cell Arteritis
1:00PM-3:00PM
Abstract Number: 0460
Baseline Glucocorticoid Toxicity in the Treatment of Giant Cell Arteritis: A Post Hoc Analysis of the GiACTA Trial
1:00PM-3:00PM
Abstract Number: 0477
Can Beta-blockers Prevent Aortic Dilation in Patients with Giant Cell Arteritis and Large Vessel Vasculitis?
1:00PM-3:00PM
Abstract Number: 0497
Classification Criteria and Existing Pre-Test Probability Stratification Tools Perform Poorly in Diagnosing Giant Cell Arteritis
1:00PM-3:00PM
Abstract Number: 0473
Comprehensive Assessment of Cranial and Orbital Vasculature on MRI in Patients with Giant Cell Arteritis
1:00PM-3:00PM
Abstract Number: 0488
Discrepancies in Temporal Artery Biopsy Positivity Rate Among White and Black Patients Suspected of Having Giant Cell Arteritis: Experience from a Tertiary Academic Medical Center
1:00PM-3:00PM
Abstract Number: 0484
Epidemiology and Predictors of Relapse in Giant Cell Arteritis: A Systematic Review and Meta-analysis
1:00PM-3:00PM
Abstract Number: 0469
Factors Associated with Corticosteroid Dosing in the Management of Giant Cell Arteritis
1:00PM-3:00PM
Abstract Number: 0486
Gene Expression Profile of Temporal Artery Tissue and Whole Blood in Giant Cell Arteritis
1:00PM-3:00PM
Abstract Number: 0489
Giant Cell Arteritis Phenotypes and Diagnosis of Aortitis Among 1852 Patients Before and After 2016 Across 10 French Referral Centers
1:00PM-3:00PM
Abstract Number: 0496
Giant Cell Arteritis Relapse Risk – Could the Extent of Vessel Involvement on Temporal and Axillary Arteries Ultrasound Be a Prognostic Marker?
1:00PM-3:00PM
Abstract Number: 0483
Giant Cell Arteritis: Physical Examination of the Superficial Temporal Arteries Can Predict Temporal Artery Biopsy Result
1:00PM-3:00PM
Abstract Number: 0481
Glucocorticoid-related Adverse Events in Giant Cell Arteritis: Application of the Glucocorticoid Toxicity Index in a Monocentric Cohort of 140 Patients
1:00PM-3:00PM
Abstract Number: 0462
Increasing Incidence of Large Artery Manifestations in Patients with Giant Cell Arteritis, a Population-based Cohort over 70 Years
1:00PM-3:00PM
Abstract Number: 0464
JAKINIB in Refractory Giant Cell Arteritis. National Multicenter Study of 15 Cases and Literature Review
1:00PM-3:00PM
Abstract Number: 0470
Long-term Efficacy of Tocilizumab Monotherapy After Ultra-short Glucocorticoid Administration to Treat Giant Cell Arteritis – One Year Follow-up of the GUSTO Trial
1:00PM-3:00PM
Abstract Number: 0492
Longitudinal Tends of Hospitalizations for Giant Cell Arteritis: A 21-year Longitudinal National Population-based Study
1:00PM-3:00PM
Abstract Number: 0491
Markers of Neutrophil Activation in Patients with ANCA-associated Vasculitis and Large-vessel Vasculitis
1:00PM-3:00PM
Abstract Number: 0493
MRI Is Superior to Ultrasound of Supraaortic Arteries in Detecting Giant Cell Arteritis – Experience of a Single Center
1:00PM-3:00PM
Abstract Number: 0476
Permanent Vision Loss in Giant Cell Arteritis: Why the Incidence Remains High
1:00PM-3:00PM
Abstract Number: 0458
Predictive Models for Thromboembolic Events in Giant Cell Arteritis: A US Veterans Health Administration Population-Based Study
1:00PM-3:00PM
Abstract Number: 0494
Risk for Visual Loss in Patients with Giant Cell Arteritis
1:00PM-3:00PM
Abstract Number: 0482
Role of miR-146a and miR-146b in Giant Cell Arteritis
1:00PM-3:00PM
Abstract Number: 0495
Seasonal Variation in the Incidence of GCA in the UK and Ireland
1:00PM-3:00PM
Abstract Number: 0471
Serum Proteomics in Giant Cell Arteritis: Findings of the Giant Cell Arteritis Treatment with Ultra-short Glucocorticoids and Tocilizumab Trial (The GUSTO Trial)
1:00PM-3:00PM
Abstract Number: 0478
Sonographic Prevalence of Subclinical GCA in Newly Diagnosed PMR
1:00PM-3:00PM
Abstract Number: 0472
The Common Carotid Artery in the Ultrasound Evaluation of Giant Cell Arteritis
1:00PM-3:00PM
Abstract Number: 0461
The Effects of Daily Prednisone and Tocilizumab on Hemoglobin A1c During the Treatment of Giant Cell Arteritis
1:00PM-3:00PM
Abstract Number: 0459
The Use of Intravenous Methylprednisolone in Patients with Giant Cell Arteritis: A Population-Based Study
1:00PM-3:00PM
Abstract Number: 0465
Tocilizumab in Large-Vessel Giant Cell Arteritis and Takayasu Arteritis: Multicentric Observational Comparative Study
1:00PM-3:00PM
Abstract Number: 0480
Treatment of Giant Cell Arteritis Patients with Ultra-short Glucocorticoids and Tocilizumab: Role of Imaging in a Prospective Study
1:00PM-3:00PM
Abstract Number: 0468
Ultrasound Wall Thickness in the Differential Diagnosis of Atherosclerosis and Large Vessel Giant Cell Arteritis
1:00PM-3:00PM
Abstract Number: 0474
Utility of Optimization of Tocilizumab Therapy in Giant Cell Arteritis: A Multicenter Study of 471 Patients
1:00PM-3:00PM
Abstract Number: 0463
Utilization of a Giant Cell Arteritis Fast-Track Program Independent of Ultrasound at a Single Center
1:00PM-3:00PM
Abstract Number: 0475
Whole-country and Regional Incidences of Giant Cell Arteritis in French Continental and Overseas Territories: A Nationwide Database Analysis

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology